Premenstrual syndrome: the effectiveness of treatment with a drospirenone-containing contraceptive
https://doi.org/10.21518/2079-701X-2015-9-49-53
Abstract
Premenstrual syndrome (PMS) is a frequent disorder associated with the menstrual cycle; treatments include a variety of medicinal and non-medicinal methods, primarily due to the absence of a common theory for the development of PMS. The majority of authors see premenstrual syndrome as a heterogeneous condition. Combined hormonal contraception is a pathogenetically substantiated method of PMS treatment. The study involved 122 patients with moderate to severe PMS. The diagnosis was confirmed by a prospective assessment of diaries. Participants received a drug containing 3 mg drospirenone and 20 µg ethinyl estradiol within 24/4 regimen. A pronounced positive effect of COC treatment was largely achieved in respect of psychological symptoms of PMS.
About the Authors
V. N. Prilepskaya
Scientific center for obstetrics, gynecology and perinatology named V.I. Kulakov, Russia’s Ministry of Health, Moscow10
Russian Federation
Russian Federation
A. V. Ledina
Scientific center for obstetrics, gynecology and perinatology named V.I. Kulakov, Russia’s Ministry of Health, Moscow10
Russian Federation
Russian Federation
References
1. O'Brien PM et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus Arch.Womens.Ment.Health. 2011. 14(1). 13-21.
2. Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives. AmJ. Obstet.Gynecol. 1994. 170(5 Pt 2). 1499-1507,
3. Freeman EW, Sondheimer SJ. Premenstrual dysphoric disorder: recognition and treatment. Primary Care Companion. J.Clin. Psychiatry. 2003. 5. 30-39
4. Finocchi C, Ferrari M. Female reproductive steroids and neuronal excitability Neurol Sci. 2011. 32. S31-35.
5. Andreen L et al. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology. 2009. 34(8). 1121-1132.
6. Halbreich U et al. Premenstrual changes and changes in gonadal hormones Acta Psychiatr Scand. 1986. 74(6). 576-586.
7. Аганезова Н.В. Ассоциация функциональных вариантов генов - транспортеров серотонина и дофамина с психовегетативными нарушениями у больных с предменструальным синдромом. VII Всероссийская научно-практическая конференция с международным участием «Молекулярная диагностика- 2010». Сборник трудов. Под ред. академика РАМН В.И. Покровского. 2010. ill, 13. 4-5.
8. Mishell DR Jr. YAZ and the novel progestin dros-pirenone J.Reprod.Med. 2008. 53(9 Suppl). 721-728.
9. Usman SB. et al. Hormonal management of premenstrual syndrome. Best. Pract. Res. Clin. Obstet. Gynaecol. 2008. 22(2). 251-260.
10. Балан В.Е., Ильина Л.М. Современный взгляд на патогенез и принципы лечения предменструального синдрома. Гинекология. 2013. 15., 6. 7-10.
11. Прилепская В.Н., Межевитинова Е.А. Предменструальный синдром. Гинекология. 2005. 7, 4. 210-214.
12. Rapkin AJ et al. Oral contraceptives and neuro-active steroids Pharmacol.Biochem.Behav. 2006. 84(4). 628-634.
13. Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or lev-onorgestrel 150 microg on premenstrual symptoms Contraception. 2005 Jan. 71(1). 1-7.
14. Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review Mol.Cell.Endocrinol. 2004. 31. 217(1-2). 255-261.
15. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000 Feb. 61(2). 105-111. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press. 1994.
16. Pearlstein TB et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005. 72(6). 414-421.
17. Yonkers KA. et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder Obstet.Gynecol. 2005. 106(3). 492-501.
18. Marr J. et al. Ethinyl estradiol 20pg/ drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder Int. J. Gynaecol Obstet. 2011. 113(2). 103-107.
19. Pinkerton JV. The menstrual cycle-mood disorder tandem: Screening, diagnosis, and treatment. OBG Management. 2011. 23. 12. 24-29.
20. Oinonen K, Mazmanian D. To what extent do oral contraceptives influence mood and affect? J.Affect.Disord.2002. 70(3). 229-240.
21. Рациональная фармакотерапия в акушерстве, гинекологии и неонатологии = Rationale for drug therapy in obstetrics, gynecology and neonatology: в 2 т.: руководство для практикующих врачей / под ред. В.Н. Серова, Г.Т. Сухих. 2-е изд., испр. и доп. М.: Литтерра, 2010.
Review
For citations:
Prilepskaya VN, Ledina AV. Premenstrual syndrome: the effectiveness of treatment with a drospirenone-containing contraceptive. Meditsinskiy sovet = Medical Council. 2015;(9):49-53. (In Russ.) https://doi.org/10.21518/2079-701X-2015-9-49-53
Views:
427
Email this article 